Daugavpils regionala slimnica SIA
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
The research at Daugavpils Regional Hospital focuses on evaluating new antimicrobial therapies and assessing safety outcomes for severe bacterial infections.
- Acute Bacterial Skin and Skin Structure Infections
- Complicated urinary tract infection (cUTI) and acute pyelonephritis
- Hospital‑acquired bacterial pneumonia
- Ventilator‑associated bacterial pneumonia
- Complicated intra‑abdominal infection
- Carbapenem‑resistant Enterobacterales infections
Across 34 trials and 19 investigators, the site contributes to advancing treatment options for resistant infections in Latvia.
Cardiovascular Diseases
Studies aim to test innovative cardiovascular therapies and preventive strategies for heart‑related events.
- Acute myocardial infarction (AMI)
- Atrial fibrillation
- Chronic heart failure and reduced ejection fraction
- Hypercholesterolemia and LDL‑C lowering
- Venous thromboembolism in cancer patients
- Hypertension and cardiovascular risk reduction
The hospital’s cardiovascular program, part of 34 active trials, seeks to improve outcomes for patients at high risk of cardiac events.
Eye Diseases
Research includes evaluating novel agents for ocular conditions, with a focus on safety and visual function improvement.
- Thyroid Eye Disease (TED)
- Dry eye and inflammatory ocular disorders
- Retinal vascular disease
Daugavpils Regional Hospital participates in several eye‑disease trials, contributing to better therapeutic options for patients.
Immune System Diseases
The site investigates targeted immunomodulators to manage chronic autoimmune conditions and assess their safety profile.
- Rheumatoid Arthritis
- Severe hypertriglyceridemia (immune‑related metabolic impact)
- Autoimmune skin disorders
With a portfolio of immune‑focused trials, the hospital supports the development of therapies that modulate the immune response.
Neoplasms
Oncology studies target tumor control and assess novel agents for a range of cancers, emphasizing efficacy and tolerability.
- Locally advanced or metastatic urothelial cancer
- Non‑muscle invasive bladder cancer
- Low‑grade upper tract urothelial cancer
- Various solid tumors evaluated with immunotherapy combinations
- Cancer‑associated venous thromboembolism
The hospital’s oncology program, part of the 34 ongoing trials, advances treatment options for patients with diverse malignancies.
Nervous System Diseases
Clinical work explores acute and chronic neurological conditions, testing interventions that aim to improve functional recovery.
- Acute ischemic stroke
- Neurological outcomes after reperfusion therapy
- Cerebrovascular event prevention in atrial fibrillation
By enrolling patients in stroke and neurovascular trials, Daugavpils Regional Hospital contributes to better neurological care.
Nutritional and Metabolic Diseases
Trials evaluate metabolic regulators and lipid‑lowering agents to address chronic metabolic disorders and their cardiovascular complications.
- Type 2 diabetes with hypertension and cardiovascular disease
- Hypertriglyceridemia and severe hypertriglyceridemia
- Chronic kidney disease with systemic inflammation
- Iron deficiency in chronic heart failure
The metabolic research portfolio supports innovative treatments that target both glycemic control and cardiovascular risk.
Respiratory Tract Diseases
The hospital conducts studies on inhaled therapies and disease‑modifying drugs to reduce exacerbations and improve lung function.
- Chronic obstructive pulmonary disease (COPD)
- Asthma (mild to moderate)
- Bronchiectasis
- Community‑acquired pneumonia and COVID‑19 pneumonia
- Severe respiratory infections requiring hospitalization
Participation in 34 trials underscores the site’s commitment to advancing respiratory care for patients in Latvia.
Skin and Connective Tissue Diseases
Research focuses on novel treatments for skin infections and inflammatory skin conditions, emphasizing safety and therapeutic benefit.
- Acute bacterial skin and skin structure infections in pediatrics
- Chronic inflammatory skin disorders
- Dermatologic manifestations of systemic diseases
Daugavpils Regional Hospital’s dermatology trials contribute to expanding options for skin‑related health issues.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 69 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 69 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Boehringer Ingelheim Espana S.A.2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Daugavpils regionala slimnica SIA
lock Showing 1 of 46 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 69 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 4 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.